LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Lista de Ações・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Fechado

SetorSaúde

16.65 2.59

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

16.14

Máximo

16.88

Indicadores-chave
By Trading Economics
Rendimento	614M 331M
Vendas	288M 731M
P/E Médio do Setor	48.586 49.888
EPS	3.16
Margem de lucro	45.287
Funcionários	835
EBITDA	628M 375M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+36.45% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-531M 1.8B
Abertura anterior	14.06
Fecho anterior	16.65

Sentimento de Notícias

By Acuity

50%

155 / 344 Ranking em Healthcare

Sarepta Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de jul. de 2025, 15:04 UTC

Grandes Movimentos do Mercado

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

21 de jul. de 2025, 11:31 UTC

Grandes Movimentos do Mercado

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

6 de mai. de 2026, 22:50 UTC

Ganhos

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

26 de jan. de 2026, 09:55 UTC

Ações em Alta

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

4 de nov. de 2025, 14:39 UTC

Ganhos

Ações em Alta

Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ

4 de nov. de 2025, 12:45 UTC

Ganhos

These Stocks Are Moving the Most Today: Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More -- Barrons.com

11 de ago. de 2025, 11:48 UTC

Ganhos

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

11 de ago. de 2025, 11:11 UTC

Ganhos

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

29 de jul. de 2025, 21:11 UTC

Ganhos

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

29 de jul. de 2025, 12:14 UTC

Ganhos

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

29 de jul. de 2025, 11:46 UTC

Ganhos

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

21 de jul. de 2025, 12:53 UTC

Ganhos

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

21 de jul. de 2025, 11:17 UTC

Ganhos

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

21 de jul. de 2025, 10:25 UTC

Ganhos

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

21 de jul. de 2025, 09:50 UTC

Ganhos

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

21 de jul. de 2025, 09:12 UTC

Ganhos

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

17 de jul. de 2025, 16:44 UTC

Ganhos

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

17 de jul. de 2025, 13:48 UTC

Ganhos

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

17 de jul. de 2025, 10:57 UTC

Ganhos

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

17 de jul. de 2025, 09:08 UTC

Ações em Alta

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

17 de jun. de 2025, 09:10 UTC

Ações em Alta

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

17 de jun. de 2025, 08:59 UTC

Ações em Alta

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

16 de jun. de 2025, 08:55 UTC

Ações em Alta

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Comparação entre Pares

Variação de preço

Sarepta Therapeutics Inc Previsão

Preço-alvo

By TipRanks

36.45% parte superior

Previsão para 12 meses

Média 22.16 USD 36.45%

Máximo 38 USD

Mínimo 5 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Sarepta Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

20 ratings

Comprar

Manter

Vender

Com base em 20 analistas que deram avaliações de ações para Sarepta Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

155 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.